Convergent Therapeuticsincis A Biotechnology Company Located In Cambridgemassachusettsfounded In 2021The Company Focuses On Developing Next Generation Targeted Radiotherapies For Cancer Treatmentaiming To Improve Patient Outcomes Through Innovative Radioantibody Technologies The Company Specializes In Alpha Radioantibodies That Deliver Alpha Emitting Payloads Directly To Cancer Cellsminimizing Radiation Exposure To Healthy Tissuesone Of Its Key Productsconv 01 Ais A Monoclonal Antibody Conjugated With 225Actargeting The Prostate Specific Membrane Antigenpsmafor Prostate Cancer Treatmentconvergent Therapeutics Is Also Exploring Dual Targeted Combination Strategies To Enhance Antitumor Efficacy With A Commitment To Advancing Cancer Therapiesconvergent Therapeutics Is Actively Involved In Clinical Trialscurrently Reaching Phase 2The Company Has Raised $132 Million In Fundingsupporting Its Growth And Research Initiatives In The Field Of Radiopharmaceutical Therapies
